PHAR

Pharming Group NV

Add to Watchlist

Advanced Chart

9.135

-0.015(-0.160%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

9.340

Open

9.3323

VWAP

9.30

Vol

2.36K

Mkt Cap

623.64M

Low

9.1349

Amount

21.95K

EV/EBITDA(TTM)

30.11

Total Shares

67.34M

646.58M

EV/OCF(TTM)

233.59

P/S(TTM)

1.85

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

2 Analyst Rating

315.99% Upside

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 38.00 USD with a low forecast of 37.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

315.99% Upside

Current: 9.135

Low

37.00

Averages

38.00

High

39.00

315.99% Upside

Current: 9.135

Low

37.00

Averages

38.00

High

39.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-21

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-14

Reiterates

Strong Buy

Reason

Oppenheimer

Michael Carrier

Buy

Maintains

$30 → $39

2025-03-14

Reason

Oppenheimer

Michael Carrier

Price Target

$30 → $39

2025-03-14

Maintains

Buy

Reason

Oppenheimer raised the firm's price target on Pharming to $39 from $30 and keeps an Outperform rating on the shares following quarterly results. The firm notes 2024 revenue of $297M came in above its/consensus' estimates of $289/262M, as well as prior top-end guidance of $295M. Addition of KL1333 to the portfolio contributes the majority of the $9 added to the firm's new price target.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2024-12-17

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2024-12-17

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2024-12-16

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2024-12-16

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pharming Group NV (PHAR.O) is -237.66, compared to its 5-year average forward P/E of -82.17. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-82.17

Current PE

-237.66

Overvalued PE

139.02

Undervalued PE

-303.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

130.70

Current EV/EBITDA

198.15

Overvalued EV/EBITDA

393.14

Undervalued EV/EBITDA

-131.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.91

Current PS

1.93

Overvalued PS

3.59

Undervalued PS

2.22